Global Vebreltinib Enteric Capsules Market Strategic Research Report

Scope of the Report

The global Vebreltinib Enteric Capsules market size is predicted to grow from US$ 3.85 million in 2025 to US$ 30.13 million in 2032; it is expected to grow at a CAGR of 34.6% from 2026 to 2032.

Vebreltinib enteric capsules are designed to provide targeted therapy for patients with MET exon 14 skipping mutations, a key oncogenic driver in non-small cell lung cancer (NSCLC) and other malignancies. As a selective MET receptor tyrosine kinase inhibitor, Vebreltinib effectively blocks MET signaling pathways, inhibiting tumor growth, proliferation, and metastasis.

In November 2023, Vebreltinib received conditional approval for the treatment of metastatic patients with MET Exon14 Skipping non-small cell lung cancer (NSCLC) from the NMPA. In China, the development rights for Vebreltinib Enteric Capsules are held by Purunao Biotech. In December 2021, Avistone announced the acquisition of Purunao Biotech, integrating Vebreltinib into its research and development pipeline. Outside mainland China, Hong Kong, and Macau, the development rights for Vebreltinib are owned by Apollomics. It is still in the clinical trial stage and has not yet been commercialized in the United States. If all goes well, it is expected to be approved by the FDA in the next few years.

At present, Vebreltinib enteric capsules have established a clear foothold in the Chinese pharmaceutical market by addressing key unmet needs in MET exon 14 skipping NSCLC and PTPRZ1-MET fusion-positive glioblastomas. As one of the first MET-targeted therapies approved in China, it has shown superior efficacy compared to existing options and has gained strong acceptance among clinicians. Its inclusion in the National Reimbursement Drug List (NRDL) significantly boosts patient access and accelerates market penetration, reinforcing its role as a leading precision oncology therapy.

Looking forward, Vebreltinib is rapidly advancing toward broader indications such as MET-amplified NSCLC. Its priority review status and active clinical pipeline position it as a central agent in China's evolving precision oncology landscape. Coupled with favorable healthcare policies that support innovative drug access and expedited regulatory review processes, Vebreltinib stands to benefit from an environment that actively promotes novel targeted therapies. This alignment between scientific innovation and policy support creates a strong foundation for long-term commercial success.

Nonetheless, the market presents challenges. The relatively small patient population with MET-driven mutations limits the addressable market. Furthermore, the emergence of global competitors—such as Capmatinib and Tepotinib—poses a threat should they enter the Chinese market. Internationally, Vebreltinib has yet to achieve commercialization, with clinical trials still underway and regulatory approvals pending. Therefore, its global expansion hinges on successful regulatory milestones, particularly FDA approval. Continued clinical validation, strategic regulatory navigation, and the establishment of global commercialization partnerships will be critical for sustaining future growth beyond China.

This report presents a comprehensive overview of the global Vebreltinib Enteric Capsules market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 25mg
• 100mg

Segment by Application

• Non-small Cell Lung Cancer
• Glioma

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Vebreltinib Enteric Capsules market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Non-small Cell Lung Cancer, Glioma evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact